Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Elanco Animal Health reported its first quarter 2026 results showing solid financial and operational performance marked by a 10% organic constant currency revenue growth, exceeding the top end of company guidance.</li><li>This growth was broad-based, supported by both volume and price increases, and spanned all major geographies and species, underscoring the company’s diversified portfolio strength.</li><li>The pet health segment, particularly in the U.S., grew 6% despite a weather-related slowdown in the early quarter, with strong rebound momentum in March and April driven by innovation products such as Zenrelia and Credelio Quattro.</li></ul>

Elanco Animal Health reported its first quarter 2026 results showing solid financial and operational performance marked by a 10% organic constant currency revenue growth, exceeding the top end of company guidance.This growth was broad-based, supported by both volume and price increases, and spanned all major geographies and species, underscoring the company’s diversified portfolio strength.The pet health segment, particularly in the U.S., grew 6% despite a weather-related slowdown in the early quarter, with strong rebound momentum in March and April driven by innovation products such as Zenrelia and Credelio Quattro.

엘랑코 동물건강의 숨겨진 성장 동력: 크레델리오 콰트로, 애드탭, 그리고 젠렐리아의 상승세!